MITO News and Press, Stealth BioTherapeutics Corp. From 07/11/22

A clinical-stage biotechnology company, Stealth BioTherapeutics ( NASDAQ: MITO ) received a letter from Nasdaq on July 7, 2022 for not meeting with minimum bid price and market value of listed securities requirements. Company requests an appeal, trading of the com...

STEALTH BIOTHERAPEUTICS ANNOUNCES RECEIPT OF NON-COMPLIANCE NOTICE FROM NASDAQ PR Newswire BOSTON , July 11, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and...

The clinical-stage biotech Stealth BioTherapeutics (NASDAQ:MITO) announced Monday that the company received a preliminary non-binding proposal to buy its shares for cash in a going-private transaction. Morningside Venture (I) Investments Ltd issued the proposal letter dated June 24, 2022, on ...

The clinical-stage biotech Stealth BioTherapeutics (NASDAQ:MITO) announced on Monday that the company received a preliminary non-binding proposal to buy its shares for cash in a going-private transaction for $0.026 per share and US$0.313 per ADS. Morningside Venture (I) Investments Ltd and J....

Stealth BioTherapeutics Corp Announces Receipt of Preliminary Non-Binding Proposal PR Newswire BOSTON , June 27, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, develo...

Clinical-stage biotech Stealth BioTherapeutics (NASDAQ:MITO) added ~14% in the pre-market Tuesday after the company announced that the FDA granted its request for a meeting that will potentially lead to approval of its lead candidate elamipretide in ultra-rare disorder Barth Syndrom...

Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome PR Newswire Type B meeting scheduled with FDA Division of Cardiology and Nephrology Company plans to discuss new clinical data that may inform a potenti...

3 Good Penny Stocks to Add to Your Watchlist Today While the stock market today is not as bullish for penny stocks as it has been in the past few days, there plenty of opportunities to be had. Now, in the past month or so, we have seen very high levels of volatility. And while bulli...

NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Novavax (NASDAQ: NVAX), Stealth BioTherapeutic...

Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium PR Newswire SBT-272 improved neuronal health, superior to other approved and investigational agents ...